Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: A population-based case-control study.


Journal

Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116

Informations de publication

Date de publication:
08 2021
Historique:
received: 07 12 2020
revised: 12 05 2021
accepted: 16 05 2021
pubmed: 22 5 2021
medline: 29 6 2021
entrez: 21 5 2021
Statut: ppublish

Résumé

There is little empirical data on the absolute benefit of cervical screening between ages 60-64y on subsequent cancer risk. We estimate the incidence of cervical cancer up to age 84y in women with and without a cervical cytology test at age 60-64y, by screening histories aged 50-59y. The current study is a population based case-control study of women born between 1928 and 1956 and aged 60-84y between 2007 and 2018. We included all such women diagnosed with cervical cancer in England and an aged-matched random sample without cancer. Women with a hysterectomy were excluded. Exposure was cervical cytology between ages 50-64y. The main outcome was 25y cumulative risk of cervical cancer between ages 60-84y. We found that eight in every 1000 (8.40, 95%CI: 7.78 to 9.07) women without a screening test between age 50-64y develop cervical cancer between the ages of 60-84y. The risk is half: 3.46 per 1000 (95%CI: 2.75 to 4.36) among women with a test between age 60-64y but no cervical screening test at age 50-59y. The absolute difference in risk is equivalent to one fewer cancer for every 202 such women screened. The highest risk (10.01, 95%CI:6.70 to 14.95) was among women with abnormal screening at ages 50-59y and no tests 60-64y. 25y risk among women with a screening test every five years between age 50-64y was just under two in a 1000 (1.59, 95%CI:1.42 to 1.78). Results suggest the upper age of screening should be dependent on previous screening participation and results.

Identifiants

pubmed: 34019928
pii: S0091-7435(21)00209-7
doi: 10.1016/j.ypmed.2021.106625
pmc: PMC8223500
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106625

Subventions

Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Am J Epidemiol. 2014 May 1;179(9):1107-14
pubmed: 24685531
CA Cancer J Clin. 2012 May-Jun;62(3):147-72
pubmed: 22422631
PLoS Med. 2014 Jan;11(1):e1001585
pubmed: 24453946
Prev Med. 2018 Sep;114:188-192
pubmed: 29981791
Lancet Oncol. 2018 Dec;19(12):1569-1578
pubmed: 30392810
J Midlife Health. 2013 Jan;4(1):40-1
pubmed: 23833533
Int J Cancer. 2013 May 1;132(9):2134-40
pubmed: 22987437
Int J Cancer. 2018 Feb 15;142(4):709-718
pubmed: 29023748
Int J Cancer. 2020 Feb 1;146(3):617-626
pubmed: 30861114
J Med Screen. 2015 Dec;22(4):207-12
pubmed: 26346038
PLoS One. 2019 Mar 26;14(3):e0214486
pubmed: 30913262
BMJ. 2005 Apr 23;330(7497):938-9
pubmed: 15695496
PLoS Med. 2017 Oct 24;14(10):e1002414
pubmed: 29065127
BJOG. 2001 Apr;108(4):388-95
pubmed: 11305546

Auteurs

Alejandra Castanon (A)

Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Cancer Prevention Group, Innovation Hub, Guys Cancer Centre, Guys Hospital, Great Maze Pond, London SE1 9RT, UK. Electronic address: alejandra.castanon@kcl.ac.uk.

Leonardo I Green (LI)

Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Cancer Prevention Group, Innovation Hub, Guys Cancer Centre, Guys Hospital, Great Maze Pond, London SE1 9RT, UK.

Peter Sasieni (P)

Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, Cancer Prevention Group, Innovation Hub, Guys Cancer Centre, Guys Hospital, Great Maze Pond, London SE1 9RT, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH